SCHEMBL3544485

SCHEMBL3544485

c1ccc(N(C2CCNCC2)C2CCNCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.48
SIGMAR1 Q99720 1/20 0.48
SLC6A2 P23975 10/20 0.46
SLC6A4 P31645 10/20 0.46
HRH1 P35367 2/20 0.46
CYP2D6 P10635 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
SCN1A P35498 1/20 0.46
KMT2A Q03164 1/20 0.46
SCN2A Q99250 1/20 0.46
SCN3A Q9NY46 1/20 0.46
GBA1 P04062 1/20 0.44
NOS2 P35228 1/20 0.41
SLC6A3 Q01959 7/20 0.40
KCNH2 Q12809 2/20 0.39
HTR2C P28335 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6738802 0.92 SLC18A3 (0.42) SLC18A3SIGMAR1SLC6A2SLC6A4HRH1
SCHEMBL2346417 0.84 TAAR1 (0.42) SLC6A2SLC6A4HRH1CYP2D6MEN1
SCHEMBL3837450 0.83 SLC6A2 (0.62) SLC18A3SIGMAR1SLC6A2SLC6A4HRH1
Hydrochloric Acid SCHEMBL18263847 0.81 SLC6A2 (0.60) SLC18A3SIGMAR1SLC6A2SLC6A4HRH1
SCHEMBL28581310 0.79 KDM4E (0.46) MEN1LMNAKMT2A
SCHEMBL4010135 0.79 SLC18A3 (0.45) SLC18A3SIGMAR1SLC6A2SLC6A4HRH1
SCHEMBL28054166 0.79 SLC18A3 (0.45) SLC18A3SIGMAR1SLC6A2SLC6A4HRH1
SCHEMBL22634123 0.79 SLC18A3 (0.45) SLC18A3SIGMAR1SLC6A2SLC6A4HRH1
Hydrochloric Acid SCHEMBL4389599 0.78 SLC6A2 (0.44) SLC18A3SIGMAR1SLC6A2SLC6A4HRH1
SCHEMBL620016 0.77 KDM4E (0.49) MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES SLC18A3 4808/4885SIGMAR1 1717/4885SLC6A2 3353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.